At present, an enormous amount of data strongly highlighted that inhibition of both NF-κB and STAT3 signaling, which are usually persistently activated in malignant tumors, could be potentially effective in suppressing inflammatory progression in cancers [44]. This evidence concerns the gene NFKB1 and cancer.